- Home
- SRFM vs ACET Comparison
SRFM vs ACET Comparison
Compare SRFM & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRFM
- ACET
- Stock Information
- Founded
- SRFM 2011
- ACET 1947
- Country
- SRFM United States
- ACET United States
- Employees
- SRFM N/A
- ACET N/A
- Industry
- SRFM Transportation Services
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- SRFM Consumer Discretionary
- ACET Health Care
- Exchange
- SRFM Nasdaq
- ACET Nasdaq
- Market Cap
- SRFM 58.2M
- ACET 64.9M
- IPO Year
- SRFM 2023
- ACET N/A
- Fundamental
- Price
- SRFM $3.71
- ACET $0.62
- Analyst Decision
- SRFM Buy
- ACET Buy
- Analyst Count
- SRFM 4
- ACET 6
- Target Price
- SRFM $5.56
- ACET $6.00
- AVG Volume (30 Days)
- SRFM 12.9M
- ACET 398.1K
- Earning Date
- SRFM 08-13-2025
- ACET 08-12-2025
- Dividend Yield
- SRFM N/A
- ACET N/A
- EPS Growth
- SRFM N/A
- ACET N/A
- EPS
- SRFM N/A
- ACET N/A
- Revenue
- SRFM $112,307,000.00
- ACET N/A
- Revenue This Year
- SRFM N/A
- ACET N/A
- Revenue Next Year
- SRFM $54.32
- ACET N/A
- P/E Ratio
- SRFM N/A
- ACET N/A
- Revenue Growth
- SRFM 31.17
- ACET N/A
- 52 Week Low
- SRFM $0.90
- ACET $0.45
- 52 Week High
- SRFM $6.72
- ACET $1.70
- Technical
- Relative Strength Index (RSI)
- SRFM 59.72
- ACET 45.85
- Support Level
- SRFM $1.77
- ACET $0.72
- Resistance Level
- SRFM $4.16
- ACET $0.68
- Average True Range (ATR)
- SRFM 0.71
- ACET 0.05
- MACD
- SRFM 0.15
- ACET -0.01
- Stochastic Oscillator
- SRFM 41.58
- ACET 21.21
About SRFM Surf Air Mobility Inc.
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.